Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance, day 10 58% Improvement Relative Risk Viral clearance, day 7 20% Viral clearance, day 14 99% c19ivm.org Qadeer et al. Ivermectin for COVID-19 LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Prospective study of 210 patients in Pakistan (Nov 2020 - May 2021) Improved viral clearance with ivermectin (p<0.000001) Qadeer et al., Pakistan J. Medical and Health Sc.., doi:10.53350/pjmhs2216824 Favors ivermectin Favors control
Ivermectin A Potential Treatment In Covid-19, Related to Critical Illness
Qadeer et al., Pakistan Journal of Medical and Health Sciences, doi:10.53350/pjmhs2216824
Qadeer et al., Ivermectin A Potential Treatment In Covid-19, Related to Critical Illness, Pakistan Journal of Medical and Health Sciences, doi:10.53350/pjmhs2216824
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective convenience sampling study of 210 hospitalized age-matched COVID-19 patients, showing faster viral clearance with ivermectin. Baseline information per group is not provided. This study is excluded in the after exclusion results of meta analysis: minimal baseline details provided.
risk of no viral clearance, 58.3% lower, RR 0.42, p < 0.001, treatment 35 of 105 (33.3%), control 84 of 105 (80.0%), NNT 2.1, mid-recovery, day 10.
risk of no viral clearance, 20.0% lower, RR 0.80, p < 0.001, treatment 84 of 105 (80.0%), control 105 of 105 (100.0%), NNT 5.0, day 7.
risk of no viral clearance, 98.6% lower, RR 0.01, p < 0.001, treatment 0 of 105 (0.0%), control 35 of 105 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Qadeer et al., 31 Aug 2022, prospective, Pakistan, peer-reviewed, median age 55.4, 6 authors, study period 1 November, 2020 - 30 May, 2021, dosage 12mg days 1-5.
Contact: darshan.kumar@duhs.edu.pk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: DOI: https://doi.org/10.53350/pjmhs2216824 ORIGINAL ARTICLE Ivermectin A Potential Treatment in Covid-19, Related to Critical Illness RASHID QADEER1, SYED MUHMMAD KASHIF2, DARSHAN KUMAR3, MADIHA MEHMMOOD4, JAWAHAR LAL5, FAIZAN6 1 Professor of Medicine, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi. Assistant Professor of Medicine, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi. Professor of Medicine, Ojha Campus, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi. 4 Consultant Medicine, Dr. Ruth K.M. Pfau Civil Hospital, Dow University Health Sciences Karachi. 5 Assistant Professor, Department Medicine, SIUT Karachi. 6 PGR, Dr. Ruth K.M. Pfau Civil Hospital Correspondence to Dr. Darshan Kumar Email: darshan.kumar@duhs.edu.pk, Cell No. +923332276994. 2 3 ABSTRACT Aim: To evaluate the potential use of ivermectin with standard therapy among mild to moderate covid-19 illness. Methods: This is a single-centered, prospective observational, randomized, parallel group (1:1 ratio), standard versus controlled ivermectin study recruited 210 confirmed COVID-19 positive patients who were admitted in COVID treatment center of Dr Ruth Kum Pafu Civil hospital Karachi, Pakistan from 1st November 2020 to 30th May 2021. Data were analyzed using SPSS version Results: Total of 210 patients were enrolled in the study and aged matched patients were divided in two groups 105 patients received ivermectin 6 mg twice a day for five days along with standard therapy while remaining 105 patients received standard therapy as per local and international guidelines. Male were 140(66.7%) and female 70(33.3%); age ranges between 26 to 77 years and majority 140( 66.7%) were more than 50 years of age. Fever, dry cough and dyspnea were the major symptoms seen; 112(53.3%) patients had DM as a comorbid illness . Total of 21(20%) of 105 patients of ivermectin group had negative PCR for COVID 19 on day seven while the other group had positive covid test in all of 105 patients . On day 10 total of 49 more patients from ivermectin group found COVID negative along with 21 previously negative had second PCR was found negative in this way total of 70( 66.7%) of ivermectin group had negative PCR for COVID 19 while 21(20%) patients from non ivermectin got negative PCR for COVID 19 on day 10 . Conclusion: Use of ivermectin with standard therapy clear the virus earlier than standard therapy in mild to moderate COVID-19 infected patients admitted in COVID treatment center of Dr Ruth Kum Pafu Civil Hospital Karachi Keywords: Covid-19, Ivermectin, Standard Therapy .
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit